Charles Schwab Investment Management Inc Regenxbio Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 387,503 shares of RGNX stock, worth $4.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
387,503
Previous 366,549
5.72%
Holding current value
$4.9 Million
Previous $2.62 Million
21.41%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding RGNX
# of Institutions
183Shares Held
45.3MCall Options Held
103KPut Options Held
100K-
Black Rock Inc. New York, NY8.61MShares$109 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.78MShares$60.4 Million4.77% of portfolio
-
Jpmorgan Chase & CO New York, NY4.36MShares$55.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.42MShares$43.2 Million0.0% of portfolio
-
State Street Corp Boston, MA1.84MShares$23.3 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $546M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...